文献速递认知障碍与痴呆脑血管病

代谢综合征与早发性痴呆:全国性人群研究

Association Between Metabolic Syndrome and Young-Onset Dementia: A Nationwide Population-Based Study.
PubMed 文献 · Neurology · 2025-04-23

该研究基于韩国国民保险服务数据,纳入2009年接受健康检查的40-60岁人群1,979,509例,随访至2020年底或65岁。代谢综合征与早发性痴呆风险升高相关(aHR 1.24,95%CI 1.19-1.30),AD风险aHR 1.12(95%CI 1.03-1.22),VaD风险aHR 1.21(95%CI 1.08-1.35)。

要点

  • 代谢综合征与早发性痴呆风险增加24%相关(aHR 1.24,95%CI 1.19-1.30)。
  • 代谢综合征与早发性AD(aHR 1.12)和VaD(aHR 1.21)风险亦相关。
  • 观察性设计无法确定因果,索赔数据可能存在错分偏倚。

核心结论

  • 在韩国大型队列中,代谢综合征及其各组分与早发性痴呆风险增加显著相关。
  • 干预代谢综合征可能有助于降低早发性痴呆风险,但观察性设计无法确立因果。

研究设计与样本

  • 全国性人群为基础队列研究,使用韩国国民保险服务数据。
  • 纳入2009年接受国家健康检查的40-60岁个体,随访至2020年12月31日或65岁。
  • 共纳入1,979,509例参与者,平均年龄49.0岁,51.3%为男性,50.7%有代谢综合征。
  • 代谢综合征依据既定指南定义,包括腰围、血压、空腹血糖、甘油三酯和高密度脂蛋白胆固醇。
  • 使用多变量Cox比例风险模型估计风险比(HR)及95%CI。

主要发现

  • 平均随访7.75年,8,921例(0.45%)发生早发性痴呆。
  • 代谢综合征与全因早发性痴呆风险升高24%相关(aHR 1.24,95%CI 1.19-1.30)。
  • 代谢综合征与早发性AD风险升高12.4%相关(aHR 1.12,95%CI 1.03-1.22)。
  • 代谢综合征与早发性VaD风险升高20.9%相关(aHR 1.21,95%CI 1.08-1.35)。
  • 与较年轻年龄(40-49 vs 50-59)、女性、饮酒状态、肥胖和抑郁存在显著交互作用。

临床怎么用

  • 研究结果提示,针对代谢综合征的干预可能有助于减轻早发性痴呆风险。

局限性

  • 观察性设计无法确定因果推断。
  • 依赖索赔数据可能引入错分偏倚。
  • 未来需纵向设计和全面数据收集验证和扩展这些关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Young-onset dementia (YOD) poses substantial societal and health care burdens. Although metabolic syndrome (MetS) is recognized as a contributor to late-onset dementia, its effect on YOD remains unclear. This study aimed to determine whether MetS and its individual components increase the risk of YOD, including all-cause dementia, Alzheimer disease (AD), and vascular dementia (VaD). METHODS: We conducted a nationwide population-based cohort study using data from the Korean National Insurance Service. Individuals aged 40-60 who underwent national health check-ups in 2009 were included and followed until December 31, 2020, or age 65, whichever came first. MetS was defined according to established guidelines, incorporating measurements of waist circumference, blood pressure, fasting glucose, triglycerides, and high-density lipoprotein cholesterol. Covariates included age, sex, income level, smoking status, alcohol consumption, and comorbidities such as hypertension, diabetes, dyslipidemia, and depression. The primary outcome was incident all-cause YOD, defined as a dementia diagnosis before age 65; secondary outcomes included young-onset AD and VaD. Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% CIs. RESULTS: A total of 1,979,509 participants (mean age, 49.0 years; 51.3% men; 50.7% with MetS) were included. Over an average follow-up of 7.75 years, 8,921 individuals (0.45%) developed YOD. MetS was associated with a 24% higher risk of all-cause YOD (adjusted HR 1.24, 95% CI 1.19-1.30), a 12.4% increased risk of AD (HR 1.12, 95% CI 1.03-1.22), and a 20.9% increased risk of VaD (HR 1.21, 95% CI 1.08-1.35). Significant interactions were noted with younger age (40-49 vs 50-59), female sex, drinking status, obesity, and depression. DISCUSSION: In this large Korean cohort, MetS and its individual components were significantly associated with an increased risk of YOD. These findings suggest that interventions targeting MetS may help mitigate YOD risk. However, the observational design precludes definitive causal inferences, and reliance on claims data could introduce misclassification bias. Future research using longitudinal designs and comprehensive data collection is needed to validate and expand on these associations.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lee JY, Han K, Kim J, et al. Association Between Metabolic Syndrome and Young-Onset Dementia: A Nationwide Population-Based Study. Neurology. 2025. PMID: 40267374. doi:10.1212/WNL.0000000000213599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。